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Background: Lgr5 (leucine-rich-repeat-containing G-protein-coupled receptor 5) has recently been identified as an
intestinal stem cell marker. In order to determine whether Lgr5 is a potential marker of cancer stem cells, we
investigated whether Lgr5 expression correlated with Ki-67 expression and prognosis in colorectal carcinoma.
Methods: Lgr5 and Ki-67 expression were evaluated by immunohistochemistry in 192 colorectal carcinoma
specimens. Selection of side population (SP) cells was performed by staining with Hoechest 33342, and Lgr5
expression in Colo205 SP cells was then detected by immunofluorescence.
Results: Lgr5 expression was significantly higher in carcinoma than in normal mucosa (P=0.001). Lgr5 was positively
correlated with histological grade (P=0.001), depth of invasion (P=0.001), lymph node metastasis (P=0.001), distant
metastasis (P=0.004), pTNM stage (P=0.001), and Ki-67 (r=0.446, P=0.001). Multivariate analysis showed that the
effect of Lgr5 on survival was independent of Ki-67 (P=0.037). In the in vitro study, Hoechst low-staining cells were
counted in 7% of the Colo205 colon cancer cell line population, and Lgr5 expression was strikingly stronger in
Hoechst low-staining cells than in high-staining cells (P=0.001).
Conclusions: These findings suggest that Lgr5 may play an important role in the progression and prognosis of
colorectal carcinoma, and may be a potential new therapeutic target for the treatment of colorectal cancer patients.
It may also be considered as a potential marker for colorectal cancer stem cells (CSCs).
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Tumor progression may be related to the alteration
of genes that regulate stem cell renewal. Patients who
experience distant metastasis usually have a shorter sur-
vival time after diagnosis. Although cancer tumors are
targeted as homogenous tissues by many therapies, re-
cent evidence suggests that considering the cancerous
tissue to be composed of heterogeneous cells, including
cancer stem cells (CSCs), may be more effective. It has
been suggested that tumors are generated and main-
tained by a small subset of cancer cells capable of multi-
differentiation and self-renewal, which are known as
CSCs [1]. A side population (SP) is a subpopulation of
cells that is distinct from the main population. SP cells
may exhibit stem cell-like characteristics. Previous stu-
dies show that there is increasing evidence for a small SP* Correspondence: chenlinbj@sina.com
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reproduction in any medium, provided the orof cancer stem cells, both from established cancer cell
lines and primary tumors [2,3]. This evidence may sup-
port a new model of tumorigenesis that involves a sub-
population of stem cells in the cancer and also the
regulation of stem cell self-renewal.
Colorectal cancer is the most common malignancy of
the gastrointestinal tract [4] and causes 655,000 deaths
worldwide every year [5]. Many treatment protocols
have been applied to colorectal cancer, but they have not
resulted in a complete cure. This may be due to colorectal
cancer stem cells (CSCs) that are resistance to radiation
therapy and chemotherapy, and may enable the recurrence
of cancers. Therefore, it is important to use therapies
that target not only proliferating cells but also stem cells
in order to cure cancer [6]. Therefore, in order to seek
out and eliminate colon CSCs, a specific biomarker is
needed. Becker et al. suggested that leucine-rich repeat-
containing G-protein-coupled receptor 5 (Lgr5) may be a
better marker for CSCs in colorectal cancer [7].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the G-protein-coupled receptor (GPCR) family of pro-
teins and is a target of Wnt signaling [8-10]. Barker
et al. recently reported that Lgr5 is a marker of murine
small intestine and colon stem cells [11]. Previous studies
demonstrated that Lgr5 is overexpressed in hepatocellular
carcinoma [10], colorectal cancer [12,13], ovarian cancer
[13], basal cell carcinoma [14], and esophageal adenocar-
cinoma [15]. Recently, it was reported that adenomatous
polyposis coli (APC) mutations exclusively in Lgr5-
positive cells could promote adenomatous growth in the
colon of mice [16]. These data suggested that Lgr5 may
play an important role in tumorigenesis. Lgr5 has also
been detected in tumor spheres derived from colon can-
cer [17]. Many authors have suggested that Lgr5 could
serve as an ideal marker of colorectal CSCs [18,19]. An
adult stem cell subpopulation, termed the ‘side popula-
tion’ (SP), has been identified that can rapidly efflux the
fluorescent dye, Hoechst 33342. SP cells have been defined
by Hoechst 33342 staining in many mammals, including
humans [20-22]. Ki-67, which is a nuclear nonhistone
protein, is a recognized nuclear antigen-specific marker
that is used to evaluate the proliferative activities of va-
rious tumors. However, to our knowledge, the relation-
ship between the expression of Lgr5 and the expression
of Ki-67 in colorectal carcinoma has not yet been inves-
tigated. In this study, we investigated the possible role
of Lgr5 expression in clinicopathology and prognosis,
as well as the relationship between Lgr5 and Ki-67 in
colorectal carcinoma. To achieve this, we selected SP
cancer stem cells by Hoechst 33342 extrusion and used
immunocytochemistry to explore the expression of Lgr5
in Hoechst33342 low-staining cancer cells in the colon
cancer cell line, Colo205. The differential expression of
Lgr5 between Hoechst 33342 low-staining cells and
high-staining cells in colon cancer was observed and
analyzed microscopically, and provided useful informa-
tion for the clinical diagnosis and treatment of CSCs.
Methods
Patients and specimens
This retrospective study consisted of 192 colorectal
adenocarcinomas with available histopathological data.
Patients were diagnosed and treated in our institute
from January 2001 to December 2004. The 80 distal nor-
mal colorectal tissues were randomly selected from the
192 cases of colorectal cancer as normal controls. Ethical
approval for this study was not required by our institu-
tion as the experiments carried out did not relate to
patients’ privacy, impairment, or treatment. The ages
of the patients ranged from 22 to 83 years (median,
62 years; mean, 58.1 years). Of the patients, 120 were
men and 72 were women. According to histological gra-
ding, 22 patients were at grade 1, 107 were at grade 2,and 63 were at grade 3. According to the clinical TNM
stage revised by the International Union Against Cancer
(UICC) in 2009, 47 patients were stage I, 70 patients
were stage II, 65 patients were stage III, and 10 patients
were stage IV. All patients were followed up for survival.
By April 2011 (the time of data analysis), 116 patients
had died and 76 patients were alive. The median survival
time was 59 months.
Cell line and cell culture
The human colon cancer cell line, Colo205 (ATCC,
Manassas, VA, USA), was cultured in RPMI 1640 medium
(GIBCO-BRL, Gaithesberg, MD) containing 10% FBS
(GIBCO-BRL, Gaithesberg, MD, USA) at 37°C in a
humidified 5% CO2/95% air atmosphere.
Immunohistochemical analysis
Immunohistochemical staining of Lgr5 and Ki-67 was
carried out as previously described [23]. Sections (4 μM
thick) were cut from paraffin blocks and mounted onto
APES-coated glass slides. The sections were deparaffi-
nized in xylene and dehydrated in a graded series of
ethanol. Antigen retrieval was performed by heating in
0.01 M citrate buffer (pH 6.0) in a microwave oven for
2 min at 100°C. The slides were then immersed in 3%
hydrogen peroxidase-methanol to inhibit endogenous
peroxidase activity. After washing with phosphate-
buffered saline (PBS), the slides were incubated with
primary monoclonal rabbit antibody to human Lgr5
(Abcam, Cambridge, MA, USA) diluted 1:50 in blocking
solution, and mouse monoclonal antibody to human
Ki-67 (Zymed Laboratories, San Francisco, CA, USA)
diluted 1:150 in blocking solution, at 4°C overnight. The
sections were then washed in PBS and incubated with
Polyperoxidase-anti-mouse/rabbit IgG (Zymed Labora-
tories, San Francisco, CA, USA) for 20 min. After
washing with PBS, 3,30-Diaminobenzidine was used as
the chromogen. Finally, the sections were counterstained
with hematoxylin. As a negative control, the primary
antibody was replaced with normal rabbit serum.
Evaluation of score
All specimens were examined by two pathologists who
did not possess knowledge of the clinical data. In case
of discrepancies, a final score was established by re-
assessment on a double-headed microscope. In scoring
Lgr5 and Ki-67 expression, both the extent and inten-
sity of the immunopositivity were considered, according
to Zhao et al. [23], Hao et al. [24], and Fan et al. [25].
The staining intensity was scored as follows: 0, negative;
1, weak; 2, moderate; 3, strong. The positivity was quanti-
fied according to the percentage of positive tumor cells:
0, <5%; 1, >5-25%; 2, >25-50%; 3, >50-75%; 4, >75%. The
final score was determined by multiplying the intensity
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12. The expression of Lgr5 and Ki-67 were regarded as
positive when the score was >5.
Microscopoic analysis for Hoechst 33342 extrusion
Cells at a concentration of 106 cells/mL were stained at
37°C for 90 min with 5 μg/mL Hoechst 33342 (Sigma,
MO, USA) in 4 mL of Dulbecco’s modified Eagle’s
medium containing 2% bovine serum albumin (BSA).
Verapamil (Sigma, MO, USA) was also added to a parallel
set of samples for 10 min before Hoechst staining to
analyze the effect of inhibiting Hoechst extrusion [26,27].
After incubation, the cells were washed with Hanks’
balanced salt solution (Invitrogen Corporation, Grand
Island, NY, USA) and fixed with 10% formalin for
120 min. Smear slides were made with Auto Smear
CF-120 (SAKURA). The cells with Hoechst 33342 extru-
sion, which were presented with a low blue fluorescence
signal or were negatively stained, were analyzed and
recorded using a BX51 fluorescent microscope (Olympus)
with a cell counter. Each experiment was performed in
triplicate and was repeated at least three times.
Fluorescent immunocytochemistry
The cells were immersed in goat serum at room tem-
perature for 15 min to block non-specific binding sites.
The slides were then incubated with a primary antibody
to Lgr5 (Abcam, Cambridge, MA, USA) overnight at
4°C. The cells were then washed with PBS and then
incubated with a goat anti-rabbit TRITC conjugatedFigure 1 An example of immunohistochemical staining for Lgr5 and
the cytoplasm of cancer cells. (A) A few scattered cells displaying Lgr5 stain
patterns in some cases of colorectal carcinoma. (D) Ki-67 protein was foundsecondary antibody (1:50 dilution; Zymed Laboratories,
San Francisco, CA, USA) for 2 h at room temperature.
Images were randomly taken at 40×10 magnification
with a digital color camera, and the Hoechst 33342
pre-stained cells with positive or negative signals from
10 images containing at least 800 cells were counted
and analyzed with image analysis software.Statistical analysis
SPSS V.13.0 (SPSS, Chicago, IL, USA) was used for stat-
istical analysis. The Pearson Chi’s square test was used
to examine the various clinicopathological characteristics
of Lgr5 and Ki-67 expression. The Spearman’s correla-
tion coefficient test was used to assess the relationship
between Lgr5 and Ki-67 expression. Univariate survival
analysis was conducted according to the Kaplan-Meier
method, and the difference between the survival curves
was analyzed with the log-rank test. Multivariate survival
analysis was performed using the Cox proportional
hazard model. Statistical significance was considered at
a value of P <0.05.Results
Expression of Lgr5 in colorectal carcinoma
Lgr5 protein was positively expressed in 56.3% (108/192)
of the colorectal carcinomas, and 25% (15/60) of distal
normal mucosa. Expression of Lgr5 protein was found
mostly in the cytoplasm of cancer cells, with some mem-
brane staining (Figure 1A, B, and C). A very significantKi-67 in colorectal carcinoma tissue. Positive expression of Lgr5 in
ing. Lgr5-positive cells exhibiting focal (B) and patchy (C) distribution
in the nucleus of cancer cells. (A-D: ×200).
Table 2 Correlations between Lgr5 and Ki-67 expression
in colorectal carcinoma
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rectal carcinoma and normal mucosa (P=0.001).Lgr5 expression P value r value
Positive Negative
Ki-67 expression
Positive 85 29 0.001 0.446
Negative 23 55
P<0.05, statistically significant.The association between Lgr5 expression and
clinicopathological features
Significant positive correlations were found between
Lgr5 expression and histological grade (P=0.001), depth
of invasion (P=0.001), lymph node metastasis (P=0.001),
and distant metastasis (P=0.004). Lgr5 expression gra-
dually increased as the pTNM stage progressed (P=0.001)
(Table 1).Table 1 Relationship of Lgr5 and Ki-67 expression to
clinicopathological variables in colorectal cancer
Variables Lgr5 P value Ki-67 P value
+ - + -
Gender
Male 66 54 P=0.652 71 49 P=0.940
Female 42 30 43 29
Age (years)
<45 18 11 P=0.791 19 10 P=0.707
45-60 32 26 35 23
≥60 58 47 60 45
Tumor size (cm)
d<5 67 61 P=0.282 66 62 P=0.006
5≤d<10 37 20 42 15
d≥10 4 3 6 1
Histological grade
1 6 16 P=0.001 10 12 P=0.001
2 52 55 54 53
3 50 13 50 13
Depth of invasion
T1 1 6 P=0.001 2 5 P=0.001
T2 19 48 24 43
T3 76 29 77 28
T4 12 1 11 2
Lymph node
N0 50 73 P=0.001 58 65 P=0.001
N1 43 8 40 11
N2 15 3 16 2
Distant metastasis
Negative 98 84 P=0.004 104 78 P=0.007
Positive 10 0 10 0
TNM stage
I 5 42 P=0.001 9 38 P=0.001
II 39 31 44 26
III 54 11 51 14
IV 10 0 10 0
P<0.05, statistically significant.Correlation between Lgr5 and Ki-67 by Spearman’s
correlation test
Ki-67 expression was positive in 59.4% (114/192) of the
colorectal carcinomas and was found in the nuclei of
cancer cells (Figure 1D). It was associated with tumor
size (P=0.006), histological grade (P=0.001), invasive
depth (P=0.001), metastasis in the regional lymph nodes
(P=0.001), distant metastasis (P=0.007), pTNM stage
(P=0.001), and prognosis (P=0.001). A positive correla-
tion between Lgr5 and Ki-67 was found (r=0.446,
P=0.001) (Table 2).Survival analysis
Follow-up data showed that the survival time of
Lgr5-positive patients was significantly shorter (mean,
39.5 ± 4.8 months) than Lgr5-negative cases (mean,
95.6 ± 7.0 months) (log-rank test, P <0.001) (Figure 2).
The overall 5-year survival rate of the Lgr5-negative
group (83.3%) was better than that of the Lgr5-positive
group (24.1%) (log-rank=80.27, P=0.001). Lgr5 expressionFigure 2 Kaplan-Meier survival analysis by Lgr5 status (n=192).
The y-axis represents the percentage of patients, and the x-axis
represents their survival in months. Lgr5-positive cases showed
significantly shorter survival than Lgr5-negative cases by log-rank
test. (P=0.001).
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(P=0.001) by the Cox proportional hazard model. Other
independent prognostic factors were age, histological
grade, distant metastasis, TNM stage, and Ki-67 (Table 3).
Hoechst low-staining cells identified in human colon
carcinoma cell line Colo205
To identify SP cells in established colon cancer cell lines,
fluorescent microscopical analysis was used to detect cells
that could effectively extrude the Hoechst 33342 dye.
This assay revealed that in Colo205 cells, 7% of the cell
population exhibited low Hoechst 33342 blue fluores-
cence, which identified them as SP cells (Figure 3A). The
SP cells with low Hoechst 33342 staining were larger in
size with pronounced round or oval nuclei, and pos-
sessed the morphological characteristics of stem-like
cells. In Colo205 cell lines, the proportion of SP cells
decreased to 0.38% following addition of the Hoechst
33342 dye transport inhibitor, verapamil.
Expression of Lgr5 in Hoechst 33342 low-staining cells
Microscopical analysis showed that Lgr5 was stained
strongly in the cytoplasm as well as the membrane. The
expression of Lgr5 was obviously much stronger in
Hoechst 33342 low-staining SP cells (76.84 ± 6.15%) than
in Hoechst 33342 high-staining cells (15.87 ± 2.49%)
(P=0.001) (Figure 3B, C, and D).
Discussion
The CSC theory has become an intensely investigated
topic, even though the origin of CSCs remains elusive
and the isolation and identification of CSCs has not been
achieved for many types of human tumor. CSCs are
defined as a small side population of tumor cells with
the ability to self-renew and potentially promote the
formation of tumors [28-30]. Conventional cancer treat-
ments indiscriminately kill proliferating cells and areTable 3 Cox regression analysis of prognostic factors in color
Prognostic variables B SE Wald
value
Gender 0.051 0.205 0.063
Age (years) 0.262 0.130 4.037
Tumor size 0.031 0.187 0.027
Histological grade 0.541 0.179 9.184
Depth of invasion 0.235 0.204 1.325
Lymph node metastasis −0.043 0.198 0.048
Distant metastasis 1.383 0.536 6.661
TNM stage 0.638 0.237 7.285
Lgr5 expression 1.018 0.274 13.842
Ki-67 expression 0.819 0.244 11.263
B, Partial regression coefficient; CI, Confidence interval; HR, Hazard ratio; SE, Standa
P<0.05, statistically significant.always unsuccessful due to the survival of quiescent
CSCs. Therefore, therapies could be designed to target
cancer stem cells by inducing their differentiation or to
eliminate them by inhibiting the maintenance of the
stem-cell state [6,31]. CSCs can survive radiation therapy
and chemotherapy and then return to a proliferative
growth state, making them good targets for biomarker
identification [15]. The cellular origin of cancer stem
cells has not been clearly determined. GPCRs have been
hypothesized to be closely associated with CSCs during
tumorigenesis [13,32]. Lgr5, a member of the GPCR
superfamily, is known as a stem cell marker in the small
intestine and colon, as well as in hair follicles [11,33].
Lgr5 over-expression has been reported in a few cancers
[10,12-15], including hepatocellular carcinoma, colorectal
cancer, ovarian cancer, basal cell carcinoma, and esopha-
geal adenocarcinoma. Recent studies suggested that Lgr5
may be involved in colorectal carcinogenesis as a target of
Wnt signaling [8,9] and may be an ideal marker of colo-
rectal CSCs [18,19]. In this study, Lgr5 was significantly
overexpressed in the majority of CRCs (56.3%) compared
with distal normal mucosa (25%). Increased expression
of Lgr5 was significantly correlated with depth of inva-
sion, lymph node metastasis, and distant metastasis.
These results suggest that high expression levels of Lgr5
receptors are usually correlated with more malignant and
metastatic tumors. Furthermore, Lgr5 was seen more fre-
quently in advanced colorectal cancer. Positive expres-
sion of Lgr5 was found in 83.1% (54/65) of stage III
cancer tissues and 100% (10/10) of stage IV cancer
tissues. These results suggest that Lgr5 may play an
important role in the development and progression of
the tumor. It was also found that Lgr5 is closed related
to the worst prognosis of colorectal carcinoma. In the
present study, Lgr5 expression correlated with poor sur-
vival of colorectal cancer, indicating that Lgr5-positive
cells may contain more CSCs. Therefore, in agreementectal carcinoma
P value HR 95% CI for HR
Lower Upper
0.802 1.053 0.705 1.572
0.045 1.299 1.006 1.677
0.869 1.031 0.715 1.487
0.002 1.718 1.211 2.438
0.250 1.264 0.848 1.885
0.824 0.957 0.649 1.412
0.010 3.989 1.395 11.405
0.007 1.894 1.191 3.010
0.001 2.768 1.619 4.732
0.001 2.267 1.406 3.657
rd error.
Figure 3 (A) Results of Hoechst 33342 staining in fixed Colo205 colon cancer cells. Red arrows indicate cells with low Hoechst 33342
staining. (B, C, D) Expression of Lgr5 in Colo205 colon cancer cells. The expression of Lgr5 was much higher in Hoechst 33342 low-staining cells
(white arrows) than in high-staining cells (P=0.001). (A, C, and D: ×400).
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sis and recurrence of colorectal cancer through multiline-
age differentiation and self-renewal after routine therapy
[17,34]. Our study also showed that Lgr5 expression was
positively correlated with Ki-67, a recognized nuclear
antigen-specific marker of cellular proliferation, suggest-
ing that Lgr5-positive cancer cells have higher prolifera-
tive activity.
Furthermore, we attempted to identify the Hoechst
33342 low-staining (SP) cancer stem-like cells in colo-
rectal cancers using immunocytochemistry after selecting
the cells that extruded Hoechst 33342. In our experi-
ments, the SP cells were observed at a frequency of 7%
in the Colo205 cell line, which was higher than reported
by Kondo [2] and Patrawala et al. [35], and also proved
the conclusion in the report by Telford et al. [36]. In
order to better recognize the SP cells directly by micros-
copy, we first used immunofluorescence to observe and
analyze the colon cancer cells expressing Lgr5 after
Hoechst33342 staining. The results demonstrated that
the expression of Lgr5 was obviously much stronger in
the Hoechst 33342 low-staining SP cells than in the other
cells. Therefore, it is suggested that the increased expres-
sion of Lgr5 may be a positive marker of SP cells in the
Colo205 colon cancer cell line. Recently, many studies
have focused on the identification of colon CSCs because
of their potential for colorectal cancer treatment [37-39].
CD133 has recently been identified as a potential cancer
stem cell marker [37,38]. However, controversy stillremained because it had been reported that CD133 ex-
pression is not restricted to intestinal stem or cancer-
initiating cells, and both CD133+ and CD133- meta-
static colon cancer cells could initiate tumors [40]. It
has been shown that CD133 expression is broadly
distributed in colorectal cancer cells [41,42]. Thus, CD133
appears to be an inappropriate marker for the char-
acterization of single colon CSCs [41]. Our results sug-
gested that the expression of Lgr5 may correspond to
the formation and function of Hoechst 33342 low-
staining SP cells in colon cancer, and may differentiate
these cells from other non-SP cells. Our results should
be considered preliminary and require further confirm-
ation by more in-depth functional studies both in cell
lines and solid tumor samples.Conclusion
In conclusion, Lgr5 is highly expressed in colorectal
cancer cells. The combined detection of Lgr5 and Ki-67
expression, to some extent, may reflect the biological
behavior of colorectal cancer. Thus Lgr5 may be a poten-
tial new therapeutic target for the treatment of colorectal
cancer patients, particularly those with advanced colorec-
tal cancer. Additionally, Lgr5 appears to be a relevant
candidate marker of colorectal CSCs. Our results are
helpful for understanding the mechanism by which
tumorigenesis is initiated, and for enabling targeted treat-
ment of CSCs to prevent relapse or metastasis.
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